Tags

Type your tag names separated by a space and hit enter

The Boston keratoprosthesis type II: the Massachusetts Eye and Ear Infirmary experience.
Cornea 2011; 30(12):1298-303C

Abstract

PURPOSE

To report the long-term outcomes of Boston keratoprosthesis type II implantation in the management of severe ocular surface disease and corneal blindness through a retrospective interventional case series.

METHODS

This retrospective review included medical records of patients who underwent Boston keratoprosthesis type II implantation at the Massachusetts Eye and Ear Infirmary from January 1, 2000 through December 31, 2009. The main outcome measures analyzed were visual acuity, keratoprosthesis retention, and postoperative complications.

RESULTS

A total of 29 eyes of 26 patients received a Boston keratoprosthesis type II during the study period. Patients undergoing operation had corneal blindness because of mucous membrane pemphigoid (51.7%), Stevens-Johnson syndrome/toxic epidermal necrolysis (41.4%), or other ocular surface disease (6.9%). Visual acuity after surgery improved to 20/200 or better in 23 eyes (79.3%) and to 20/30 or better in 10 eyes (34.5%). In patients with at least 1 year of follow-up (n = 21), visual acuity of 20/200 or better was maintained in 12 eyes (57.1%). Of 13 eyes followed-up for more than 5 years, 6 eyes (46.2%) had visual acuity of 20/200 or better at the last follow-up examination. Eyes that did not improve to 20/200 or lost vision during the follow-up had end-stage glaucoma, previous retinal detachment, or age-related macular degeneration. Of the total of 29 eyes, 17 devices (58.6%) were retained without extrusion or replacement during a total follow-up time of 107.9 person-years.

CONCLUSIONS

The Boston keratoprosthesis type II is a viable option for corneal blindness from severe autoimmune ocular surface diseases.

Authors+Show Affiliations

Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA 02114, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21963861

Citation

Pujari, Siddharth, et al. "The Boston Keratoprosthesis Type II: the Massachusetts Eye and Ear Infirmary Experience." Cornea, vol. 30, no. 12, 2011, pp. 1298-303.
Pujari S, Siddique SS, Dohlman CH, et al. The Boston keratoprosthesis type II: the Massachusetts Eye and Ear Infirmary experience. Cornea. 2011;30(12):1298-303.
Pujari, S., Siddique, S. S., Dohlman, C. H., & Chodosh, J. (2011). The Boston keratoprosthesis type II: the Massachusetts Eye and Ear Infirmary experience. Cornea, 30(12), pp. 1298-303. doi:10.1097/ICO.0b013e318215207c.
Pujari S, et al. The Boston Keratoprosthesis Type II: the Massachusetts Eye and Ear Infirmary Experience. Cornea. 2011;30(12):1298-303. PubMed PMID: 21963861.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Boston keratoprosthesis type II: the Massachusetts Eye and Ear Infirmary experience. AU - Pujari,Siddharth, AU - Siddique,Sana S, AU - Dohlman,Claes H, AU - Chodosh,James, PY - 2011/10/4/entrez PY - 2011/10/4/pubmed PY - 2012/1/18/medline SP - 1298 EP - 303 JF - Cornea JO - Cornea VL - 30 IS - 12 N2 - PURPOSE: To report the long-term outcomes of Boston keratoprosthesis type II implantation in the management of severe ocular surface disease and corneal blindness through a retrospective interventional case series. METHODS: This retrospective review included medical records of patients who underwent Boston keratoprosthesis type II implantation at the Massachusetts Eye and Ear Infirmary from January 1, 2000 through December 31, 2009. The main outcome measures analyzed were visual acuity, keratoprosthesis retention, and postoperative complications. RESULTS: A total of 29 eyes of 26 patients received a Boston keratoprosthesis type II during the study period. Patients undergoing operation had corneal blindness because of mucous membrane pemphigoid (51.7%), Stevens-Johnson syndrome/toxic epidermal necrolysis (41.4%), or other ocular surface disease (6.9%). Visual acuity after surgery improved to 20/200 or better in 23 eyes (79.3%) and to 20/30 or better in 10 eyes (34.5%). In patients with at least 1 year of follow-up (n = 21), visual acuity of 20/200 or better was maintained in 12 eyes (57.1%). Of 13 eyes followed-up for more than 5 years, 6 eyes (46.2%) had visual acuity of 20/200 or better at the last follow-up examination. Eyes that did not improve to 20/200 or lost vision during the follow-up had end-stage glaucoma, previous retinal detachment, or age-related macular degeneration. Of the total of 29 eyes, 17 devices (58.6%) were retained without extrusion or replacement during a total follow-up time of 107.9 person-years. CONCLUSIONS: The Boston keratoprosthesis type II is a viable option for corneal blindness from severe autoimmune ocular surface diseases. SN - 1536-4798 UR - https://www.unboundmedicine.com/medline/citation/21963861/The_Boston_keratoprosthesis_type_II:_the_Massachusetts_Eye_and_Ear_Infirmary_experience_ L2 - http://Insights.ovid.com/pubmed?pmid=21963861 DB - PRIME DP - Unbound Medicine ER -